Skip to main content
SpringerLink
Log in

Drug Treatment of Pulmonary Arterial Hypertension

Current and Future Agents

  • Therapy in Practice
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

During the last decade we have witnessed substantial improvements in the therapeutic options for pulmonary arterial hypertension (PAH), including true innovations targeting some of the mechanisms involved in the pathogenesis of this devastating disease. Intravenous epoprostenol was the first drug to improve symptoms and survival of patients with PAH. Novel prostanoids, including subcutaneous treprostinil and inhaled iloprost, also have beneficial effects in many patients, although their long-term efficacy is less well known. Among the newer treatments for PAH, endothelin receptor antagonists and phosphodiesterase type 5 (PDE5) inhibitors have reshaped clinical practice. The endothelin receptor antagonist bosentan has been approved in many parts of the world and most current guidelines recommend this drug as first-line treatment for patients with PAH in functional class III. Novel endothelin receptor antagonists such as sitaxsentan sodium and ambrisentan are currently being investigated. The PDE5 sildenafil is also being intensively studied in patients with pulmonary hypertension, and most of the available data look promising, although approval for PAH is still pending. Other PDE5 inhibitors have not yet undergone extensive study in PAH. The increasing insight into the pathogenesis of PAH opens several new therapeutic opportunities, which include vasoactive intestinal peptide, selective serotonin reuptake inhibitors, adrenomedullin and HMG-CoA reductase inhibitors (statins). However, PAH is a complex disorder and targeting a single pathway can not be expected to be uniformly successful. Thus, combining substances with different modes of action is expected to improve symptoms, haemodynamics and survival in PAH patients, although combination therapy has yet to undergo the scrutiny of large randomised clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1

Similar content being viewed by others

References

  1. Reitz BA, Wallwork JL, Hunt SA, et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 1982 Mar 11; 306(10): 557–64

    Article  PubMed  CAS  Google Scholar 

  2. Galie N, Seeger W, Naeije R, et al. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004 Jun 16; 43 (12 Suppl.): S81–8

    Article  Google Scholar 

  3. Hoeper MM, Oudiz RJ, Peacock A, et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 2004; 43 (12 Suppl.): S48–55

    Article  Google Scholar 

  4. Hoeper MM, Galie N, Simonneau G, et al. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165(9): 1209–16

    Article  PubMed  Google Scholar 

  5. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351(14): 1425–36

    Article  PubMed  CAS  Google Scholar 

  6. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl.): S13–24

    Article  Google Scholar 

  7. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl.): S5–S12

    Article  Google Scholar 

  8. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336(2): 111–7

    Article  PubMed  CAS  Google Scholar 

  9. Rubin LJ, Galie N. Pulmonary arterial hypertension: a look to the future. J Am Coll Cardiol 2004; 43 (12 Suppl.): S89–90

    Article  Google Scholar 

  10. Rubin LJ. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004 Jul; 126 (1 Suppl.): 7S–10S

    Article  PubMed  Google Scholar 

  11. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl.): S40–7

    Article  Google Scholar 

  12. Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl.): S56–61

    Article  CAS  Google Scholar 

  13. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126 (1 Suppl.): 35S–62S

    Article  PubMed  Google Scholar 

  14. Klepetko W, Mayer E, Sandoval J, et al. Interventional and surgical modalities of treatment for pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl.): S73–80

    Article  Google Scholar 

  15. Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl.): S25–32

    Article  Google Scholar 

  16. Newman JH, Trembath RC, Morse JA, et al. Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol 2004; 43 (12 Suppl.): S33–9

    Article  CAS  Google Scholar 

  17. Fedullo PF, Auger WR, Kerr KM, et al. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001; 345(20): 1465–72

    Article  PubMed  CAS  Google Scholar 

  18. Dartevelle P, Fadel E, Mussot S, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2004; 23(4): 637–48

    Article  PubMed  CAS  Google Scholar 

  19. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: the Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334(5): 296–302

    Article  PubMed  CAS  Google Scholar 

  20. Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999; 160: 600–7

    PubMed  CAS  Google Scholar 

  21. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997; 134(1): 44–54

    Article  PubMed  CAS  Google Scholar 

  22. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: the Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004 Dec; 25(24): 2243–78

    Article  PubMed  Google Scholar 

  23. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70: 580–7

    Article  PubMed  CAS  Google Scholar 

  24. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327(2): 76–81

    Article  PubMed  CAS  Google Scholar 

  25. Hoeper MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension: German PPH Study Group. J Am Coll Cardiol 2000 Jan; 35(1): 176–82

    Article  PubMed  CAS  Google Scholar 

  26. Sitbon O, Humbert M, Ioos V. Who benefits from long-term calcium channel blocker therapy for primary pulmonary hypertension? [abstract]. Am J Respir Crit Care Med 2003; 167: A440

    Google Scholar 

  27. Woodmansey PA, O’Toole L, Channer KS, et al. Acute pulmonary vasodilatory properties of amlodipine in humans with pulmonary hypertension. Heart 1996; 75(2): 171–3

    Article  PubMed  CAS  Google Scholar 

  28. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002 Aug 21; 40(4): 780–8

    Article  PubMed  CAS  Google Scholar 

  29. Higenbottam TW, Butt AY, Dinh-Xaun AT, et al. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart 1998; 79(2): 175–9

    PubMed  CAS  Google Scholar 

  30. Higenbottam T, Butt AY, McMahon A, et al. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998; 80(2): 151–5

    PubMed  CAS  Google Scholar 

  31. Humbert M. Improving survival in pulmonary arterial hypertension. Eur Respir J 2005 Feb; 25(2): 218–20

    Article  PubMed  CAS  Google Scholar 

  32. Hoeper MM, Dinh-Xuan AT. Combination therapy for pulmonary arterial hypertension: still more questions than answers. Eur Respir J 2004 Sep; 24(3): 339–40

    Article  PubMed  CAS  Google Scholar 

  33. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327(2): 70–5

    Article  PubMed  CAS  Google Scholar 

  34. Tuder RM, Cool CD, Gearci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159: 1925–32

    PubMed  CAS  Google Scholar 

  35. Higenbottam T, Wheeldon D, Wells F, et al. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984; I(8385): 1046–7

    Article  Google Scholar 

  36. Rubin LJ, Groves BM, Reeves JT, et al. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 1982 Aug; 66(2): 334–8

    Article  PubMed  CAS  Google Scholar 

  37. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000; 132(6): 425–34

    PubMed  CAS  Google Scholar 

  38. Clapp LH, Finney P, Turcato S, et al. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 2002; 26(2): 194–201

    PubMed  CAS  Google Scholar 

  39. Hoeper MM, Voelkel NF, Bates TO, et al. Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and in rat lungs via cAMP. Am J Respir Cell Mol Biol 1997; 17: 748–56

    Google Scholar 

  40. Jones DA, Benjamin CW, Linseman DA. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol 1995; 48(5): 890–6

    PubMed  CAS  Google Scholar 

  41. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106(12): 1477–82

    Article  PubMed  CAS  Google Scholar 

  42. Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999; 34: 1995–6

    Article  Google Scholar 

  43. Humbert M, Sanchez O, Fartoukh M, et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J 1999; 13(6): 1351–6

    Article  PubMed  CAS  Google Scholar 

  44. Grant SM, Goa KL. Iloprost: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischemia and extracorporeal circulation procedures. Drugs 1992; 43(6): 889–924

    Article  PubMed  CAS  Google Scholar 

  45. Olschewski H, Walmrath D, Schermuly R, et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996; 124(9): 820–4

    PubMed  CAS  Google Scholar 

  46. Olschewski H, Rohde B, Behr J, et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest 2003; 124(4): 1294–304

    Article  PubMed  CAS  Google Scholar 

  47. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347(5): 322–9

    Article  PubMed  CAS  Google Scholar 

  48. Olschewski H, Ghofrani HA, Schmehl T, et al. Inhaled iloprost to treat severe pulmonary hypertension: an uncontrolled trial. German PPH Study Group. Ann Intern Med 2000 Mar 21; 132(6): 435–43

    CAS  Google Scholar 

  49. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000 Jun 22; 342(25): 1866–70

    Article  PubMed  CAS  Google Scholar 

  50. Machherndl S, Kneussl M, Baumgartner H, et al. Long-term treatment of pulmonary hypertension with aerosolized iloprost. Eur Respir J 2001; 17: 8–13

    Article  PubMed  CAS  Google Scholar 

  51. Schenk P, Petkov V, Madl C, et al. Aerosolized iloprost therapy could not replace long-term iv epoprostenol (prostacyclin) administration in severe pulmonary hypertension. Chest 2001; 119: 296–300

    Article  PubMed  CAS  Google Scholar 

  52. Chattaraj SC. Treprostinil sodium: Pharmacia. Curr Opin Investig Drugs 2002 Apr; 3(4): 582–6

    PubMed  CAS  Google Scholar 

  53. Budev MM, Minai OA, Arroliga AC. Overview of treprostinil sodium for the treatment of pulmonary arterial hypertension. Drugs Today (Barc) 2004 Mar; 40(3): 225–34

    Article  CAS  Google Scholar 

  54. McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003; 41(2): 293–9

    Article  PubMed  CAS  Google Scholar 

  55. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165(6): 800–4

    PubMed  Google Scholar 

  56. Vachiery JL, Hill N, Zwicke D, et al. Transitioning from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest 2002; 121(5): 1561–5

    Article  PubMed  CAS  Google Scholar 

  57. Galie N, Manes A, Branzi A. The new clinical trials on pharmacological treatment in pulmonary arterial hypertension. Eur Respir J 2002; 20(4): 1037–49

    Article  PubMed  CAS  Google Scholar 

  58. Okano Y, Yoshioka T, Shimouchi A, et al. Orally active prostacyclin analogue in primary pulmonary hypertension [letter; published erratum appears in Lancet 1997 Nov 8; 350 (9088): 1406]. Lancet 1997; 349(9062): 1365

    Article  PubMed  CAS  Google Scholar 

  59. Nagaya N, Uematsu M, Okano Y, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999; 34(4): 1188–92

    Article  PubMed  CAS  Google Scholar 

  60. Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39(9): 1496–502

    Article  PubMed  CAS  Google Scholar 

  61. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41(12): 2119–25

    Article  PubMed  CAS  Google Scholar 

  62. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993 Jun 17; 328(24): 1732–9

    Article  PubMed  CAS  Google Scholar 

  63. Galie N, Grigioni F, Bacchi-Reggiani L. Relation of endothelin-1 to survival in patients with primary pulmonary hypertension [abstract]. Eur J Clin Invest 1996; 26(273): A48

    Google Scholar 

  64. Rubens C, Ewert R, Halank M, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001; 120(5): 1562–9

    Article  PubMed  CAS  Google Scholar 

  65. Chen YF, Oparil S. Endothelin and pulmonary hypertension. J Cardiovasc Pharmacol 2000; 35 (4 Suppl. 2): S49–53

    Article  PubMed  CAS  Google Scholar 

  66. Chen YF, Oparil S. Endothelial dysfunction in the pulmonary vascular bed. Am J Med Sci 2000 Oct; 320(4): 223–32

    Article  PubMed  CAS  Google Scholar 

  67. Lüscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000; 102: 2434–40

    Article  PubMed  Google Scholar 

  68. Davie N, Haleen SJ, Upton PD, et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002; 165(3): 398–405

    PubMed  Google Scholar 

  69. Bauer M, Wilkens H, Langer F, et al. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 2002 Mar 5; 105(9): 1034–6

    Article  PubMed  CAS  Google Scholar 

  70. Prakash A, Perry CM. Bosentan. Am J Cardiovasc Drugs 2002; 2(5): 335–43

    Article  PubMed  CAS  Google Scholar 

  71. Rubin LJ, Roux S. Bosentan: a dual endothelin receptor antagonist. Expert Opin Investig Drugs 2002; 11(7): 991–1002

    Article  PubMed  CAS  Google Scholar 

  72. Weber C, Banken L, Birnboeck H, et al. Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1999; 39(8): 847–54

    Article  PubMed  CAS  Google Scholar 

  73. Murphey LM, Hood EH. Bosentan and warfarin interaction. Ann Pharmacother 2003; 37(7): 1028–31

    Article  PubMed  Google Scholar 

  74. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001 Oct 6; 358(9288): 1119–23

    Article  PubMed  CAS  Google Scholar 

  75. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346(12): 896–903

    Article  PubMed  CAS  Google Scholar 

  76. Galie N, Hinderliter AL, Torbicki A, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41(8): 1380–6

    Article  PubMed  CAS  Google Scholar 

  77. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005 Feb; 25(2): 244–9

    Article  PubMed  CAS  Google Scholar 

  78. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169(4): 441–7. Epub 2003 Nov 20

    Article  PubMed  Google Scholar 

  79. Wu C, Chan MF, Stavros F, et al. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med Chem 1997 May 23; 40(11): 1690–7

    Article  PubMed  CAS  Google Scholar 

  80. Barst RJ, Rich S, Widlitz A, et al. Clinical efficacy of sitaxsentan, an endothelin-a receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002; 121(6): 1860–8

    Article  PubMed  CAS  Google Scholar 

  81. Billman GE. Ambrisentan (Myogen). Curr Opin Investig Drugs 2002; 3(10): 1483–6

    PubMed  CAS  Google Scholar 

  82. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995 Oct; 75(4): 725–48

    PubMed  CAS  Google Scholar 

  83. Ahn HS, Foster M, Cable M, et al. Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. Adv Exp Med Biol 1991; 308: 191–7

    Article  PubMed  CAS  Google Scholar 

  84. Cheitlin MD, Hutter AM, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease: technology and practice executive committee. Circulation 1999; 99: 168–77

    Article  PubMed  CAS  Google Scholar 

  85. Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000; 84(2): E4

    Article  PubMed  CAS  Google Scholar 

  86. Bharani A, Mathew V, Sahu A, et al. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. Indian Heart J 2003 Jan–Feb; 55(1): 55–9

    PubMed  Google Scholar 

  87. Karatza AA, Narang I, Rosenthal M, et al. Treatment of primary pulmonary hypertension with oral sildenafil. Respiration 2004 Mar–Apr; 71(2): 192–4

    Article  PubMed  CAS  Google Scholar 

  88. Kothari SS, Duggal B. Chronic oral sildenafil therapy in severe pulmonary artery hypertension. Indian Heart J 2002 Jul–Aug; 54(4): 404–9

    PubMed  Google Scholar 

  89. Laupland KB, Helmersen D, Zygun DA, et al. Sildenafil treatment of primary pulmonary hypertension. Can Respir J 2003 Jan–Feb; 10(1): 48–50

    PubMed  Google Scholar 

  90. Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002; 105(20): 2398–403

    Article  PubMed  CAS  Google Scholar 

  91. Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003 Oct 28; 108(17): 2066–9. Epub 2003 Oct 20

    Article  PubMed  CAS  Google Scholar 

  92. Mikhail GW, Prasad SK, Li W, et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur Heart J 2004; 25(5): 431–6

    Article  PubMed  CAS  Google Scholar 

  93. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension [letter]. N Engl J Med 2000; 343: 1342

    Article  PubMed  CAS  Google Scholar 

  94. Sastry BK, Narasimhan C, Reddy NK, et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004; 43(7): 1149–53

    Article  PubMed  CAS  Google Scholar 

  95. Sastry BK, Narasimhan C, Reddy NK, et al. A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. Indian Heart J 2002 Jul–Aug; 54(4): 410–4

    PubMed  CAS  Google Scholar 

  96. Zimmermann AT, Calvert AF, Veitch EM. Sildenafil improves right-ventricular parameters and quality of life in primary pulmonary hypertension. Intern Med J 2002 Aug; 32(8): 424–6

    Article  PubMed  CAS  Google Scholar 

  97. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136(7): 515–22

    PubMed  CAS  Google Scholar 

  98. Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003; 42(1): 158–64

    Article  PubMed  CAS  Google Scholar 

  99. Jimenez Lopez-Guarch C, Escribano Subias P, Tello de Meneses R, et al. Efficacy of oral sildenafil as rescue therapy in patients with severe pulmonary arterial hypertension chronically treated with prostacyclin: long-term results. Rev Esp Cardiol 2004; 57(10): 946–51

    Article  PubMed  Google Scholar 

  100. Kuhn KP, Wickersham NE, Robbins IM, et al. Acute effects of sildenafil in patients with primary pulmonary hypertension receiving epoprostenol. Exp Lung Res 2004; 30(2): 135–45

    Article  PubMed  CAS  Google Scholar 

  101. Stiebellehner L, Petkov V, Vonbank K, et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest 2003; 123(4): 1293–5

    Article  PubMed  Google Scholar 

  102. Wilkens H, Guth A, Konig J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001 Sep 11; 104(11): 1218–22

    Article  PubMed  CAS  Google Scholar 

  103. Palmieri EA, Affuso F, Fazio S, et al. Tadalafil in primary pulmonary arterial hypertension. Ann Intern Med 2004 Dec 2; 141(9): 743–4

    PubMed  Google Scholar 

  104. Ghofrani HA, Voswinckel R, Reichenberger F, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004 Oct 6; 44(7): 1488–96

    PubMed  CAS  Google Scholar 

  105. Granton JT, Rabinovitch M. Pulmonary arterial hypertension in congenital heart disease. Cardiol Clin 2002 Aug; 20(3): 441–57, vii

    Article  PubMed  Google Scholar 

  106. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99: 1858–65

    Article  PubMed  CAS  Google Scholar 

  107. McLaughlin VV, Genthner DE, Panella MM, et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999; 130: 740–3

    PubMed  CAS  Google Scholar 

  108. Kuhn KP, Byrne DW, Arbogast PG, et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003 Feb 15; 167(4): 580–6

    Article  PubMed  Google Scholar 

  109. Christensen DD, McConnell ME, Book WM, et al. Initial experience with bosentan therapy in patients with the Eisenmenger syndrome. Am J Cardiol 2004 Jul 15; 94(2): 261–3

    Article  PubMed  CAS  Google Scholar 

  110. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004; 363(9419): 1461–8

    Article  PubMed  Google Scholar 

  111. Krowka MJ, Frantz RP, McGoon MD, et al. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999; 30(3): 641–8

    Article  PubMed  CAS  Google Scholar 

  112. Kuo PC, Johnson LB, Plotkin JS, et al. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997; 63(4): 604–6

    Article  PubMed  CAS  Google Scholar 

  113. Makisalo H, Koivusalo A, Vakkuri A, et al. Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation. Liver Transpl 2004 Jul; 10(7): 945–50

    Article  PubMed  Google Scholar 

  114. Hoeper MM, Halank M, Marx C, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005 Mar; 25(3): 502–8

    Article  PubMed  CAS  Google Scholar 

  115. Opravil M, Pechere M, Speich R, et al. HIV-associated primary pulmonary hypertension: a case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997; 155(3): 990–5

    CAS  Google Scholar 

  116. Pellicelli AM, Palmieri F, Cicalini S, et al. Pathogenesis of HIV-related pulmonary hypertension. Ann N Y Acad Sci 2001; 946: 82–94

    Article  PubMed  CAS  Google Scholar 

  117. Zuber JP, Calmy A, Evison JM, et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 2004; 38(8): 1178–85. Epub 2004 Apr 1

    Article  PubMed  Google Scholar 

  118. Speich R, Jenni R, Opravil M, et al. Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy. Swiss Med Wkly 2001 Dec 1; 131(45–46): 663–5

    PubMed  CAS  Google Scholar 

  119. Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2000; 162: 1846–50

    PubMed  CAS  Google Scholar 

  120. Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003 May 15; 167(10): 1433–9

    Article  PubMed  Google Scholar 

  121. Cea-Calvo L, Escribano Subias P, Tello De Menesses R, et al. Treatment of HIV-associated pulmonary hypertension with treprostinil. Rev Esp Cardiol 2003; 56(4): 421–5

    Article  PubMed  Google Scholar 

  122. Sitbon O, Gressin V, Speich R, et al. Bosentan for human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004 Dec 1; 170(11): 1212–7. Epub 2004 Aug 18

    Article  PubMed  Google Scholar 

  123. Alp S, Schlottmann R, Bauer TT, et al. Long-time survival with HIV-related pulmonary arterial hypertension: a case report. AIDS 2003 Jul 25; 17(11): 1714–5

    Article  PubMed  Google Scholar 

  124. Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000; 162: 1964–73

    PubMed  CAS  Google Scholar 

  125. Resten A, Maitre S, Humbert M, et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. AJR Am J Roentgenol 2004 Jul; 183(1): 65–70

    PubMed  Google Scholar 

  126. Resten A, Maitre S, Humbert M, et al. Pulmonary arterial hypertension: thin-section CT predictors of epoprostenol therapy failure. Radiology 2002; 222(3): 782–8

    Article  PubMed  Google Scholar 

  127. Dufour B, Maitre S, Humbert M, et al. High-resolution CT of the chest in four patients with pulmonary capillary hemangiomatosis or pulmonary venoocclusive disease. AJR Am J Roentgenol 1998; 171(5): 1321–4

    PubMed  CAS  Google Scholar 

  128. Palmer SM, Robinson LJ, Wang A, et al. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest 1998; 113(1): 237–40

    Article  PubMed  CAS  Google Scholar 

  129. Humbert M, Maitre S, Capron F, et al. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. Am J Respir Crit Care Med 1998; 157 (5 Pt 1): 1681–5

    PubMed  CAS  Google Scholar 

  130. Gugnani MK, Pierson C, Vanderheide R, et al. Pulmonary edema complicating prostacyclin therapy in pulmonary hypertension associated with scleroderma: a case of pulmonary capillary hemangiomatosis. Arthritis Rheum 2000; 43: 699–703

    Article  PubMed  CAS  Google Scholar 

  131. Davis LL, deBoisblanc BP, Glynn CE, et al. Effect of prostacyclin on microvascular pressures in a patient with pulmonary veno-occlusive disease. Chest 1995; 108(6): 1754–6

    Article  PubMed  CAS  Google Scholar 

  132. Petkov V, Mosgoeller W, Ziesche R, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003; 111(9): 1339–46

    PubMed  CAS  Google Scholar 

  133. Nagaya N, Kyotani S, Uematsu M, et al. Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension. Circulation 2004 Jan 27; 109(3): 351–6

    Article  PubMed  Google Scholar 

  134. Upton PD, Wharton J, Davie N, et al. Differential adrenomedullin release and endothelin receptor expression in distinct sub-populations of human airway smooth-muscle cells. Am J Respir Cell Mol Biol 2001; 25(3): 316–25

    PubMed  CAS  Google Scholar 

  135. Upton PD, Wharton J, Coppock H, et al. Adrenomedullin expression and growth inhibitory effects in distinct pulmonary artery smooth muscle cell subpopulations. Am J Respir Cell Mol Biol 2001; 24(2): 170–8

    PubMed  CAS  Google Scholar 

  136. Nagaya N, Nishikimi T, Uematsu M, et al. Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension. Heart 2000; 84(6): 653–8

    Article  PubMed  CAS  Google Scholar 

  137. Nagaya N, Miyatake K, Kyotani S, et al. Pulmonary vasodilator response to adrenomedullin in patients with pulmonary hypertension. Hypertens Res 2003; 26 Suppl.: S141–6

    Article  PubMed  CAS  Google Scholar 

  138. Kandier MA, Von Der Hardt K, Mahfoud S, et al. Pilot intervention: aerosolized adrenomedullin reduces pulmonary hypertension. J Pharmacol Exp Ther 2003 Sep; 306(3): 1021–6. Epub 2003 May 15

    Article  CAS  Google Scholar 

  139. Westphal M, Booke M, Dinh-Xuan AT. Adrenomedullin: a smart road from pheochromocytoma to treatment of pulmonary hypertension. Eur Respir J 2004 Oct; 24(4): 518–20

    Article  PubMed  CAS  Google Scholar 

  140. Nishimura T, Faul JL, Berry GJ, et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 2002 Nov 15; 166(10): 1403–8. Epub 2002 Aug 15

    Article  PubMed  Google Scholar 

  141. Girgis RE, Li D, Zhan X, et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 2003 Sep; 285(3): H938–45. Epub 2003 May 15

    PubMed  CAS  Google Scholar 

  142. Nishimura T, Vaszar LT, Faul JL, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003 Sep 30; 108(13): 1640–5. Epub 2003 Sep 8

    Article  PubMed  CAS  Google Scholar 

  143. Herve P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99(3): 249–54

    Article  PubMed  CAS  Google Scholar 

  144. Eddahibi S, Adnot S, Frisdal E, et al. Dexfenfluramine-associated changes in 5-hydroxytryptamine transporter expression and development of hypoxic pulmonary hypertension in rats. J Pharmacol Exp Ther 2001 Apr; 297(1): 148–54

    PubMed  CAS  Google Scholar 

  145. Baumann MH, Ayestas MA, Dersch CM, et al. Serotonin transporters, serotonin release, and the mechanism of fenfluramine neurotoxicity. Ann N Y Acad Sci 2000; 914: 172–86

    Article  PubMed  CAS  Google Scholar 

  146. Belohlavkova S, Simak J, Kokesova A, et al. Fenfluramine-induced pulmonary vasoconstriction: role of serotonin receptors and potassium channels. J Appl Physiol 2001 Aug; 91(2): 755–61

    PubMed  CAS  Google Scholar 

  147. Rothman RB, Ayestas MA, Dersch CM, et al. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation 1999 Aug 24; 100(8): 869–75

    CAS  Google Scholar 

  148. Eddahibi S, Humbert M, Fadel E, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001; 108(8): 1141–50

    PubMed  CAS  Google Scholar 

  149. Eddahibi S, Chaouat A, Morrell N, et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 2003; 108(15): 1839–44

    Article  PubMed  CAS  Google Scholar 

  150. Marcos E, Adnot S, Pham MH, et al. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med 2003 Aug 15; 168(4): 487–93. Epub 2003 May 28

    Article  PubMed  Google Scholar 

  151. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004 Sep; 24(3): 353–9

    Article  PubMed  CAS  Google Scholar 

  152. Hoeper MM, Taha N, Bekjarova A, et al. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 2003; 22(2): 330–4

    Article  PubMed  CAS  Google Scholar 

  153. Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004 Dec; 24(6): 1007–10

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used in the preparation of this manuscript. Dr Hoeper has received speaker fees from Actelion Pharmaceuticals (manufacturer of bosentan), Schering (manufacturer of iloprost in Europe) and Pfizer (manufacturer of sildenafil). He has received consultant fees from CoTherix (distributor of iloprost in the US) and is a member of an international medical advisory board for Actelion Pharmaceuticals.

Author information

Authors and Affiliations

  1. Department of Respiratory Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover, 30625, Germany

    Marius M. Hoeper

Authors
  1. Marius M. Hoeper
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marius M. Hoeper.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoeper, M.M. Drug Treatment of Pulmonary Arterial Hypertension. Drugs 65, 1337–1354 (2005). https://doi.org/10.2165/00003495-200565100-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200565100-00003

Keywords

Search

Navigation